In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes.
The in vivo efficacy of virus- and tumor-specific cytotoxic T lymphocytes (CTL) is discussed as well as ways to activate these cells in vivo with lymphokines, monoclonal antibodies and immunization. In vivo and in vitro peptide immunization can induce such virus- and tumor-specific CTL but several questions have to be answered before peptide vaccination can be implemented as a novel immunotherapeutic or preventive approach in man.
Kast
W M
WM
Department of Immunohematology, University Hospital, Leiden, The Netherlands.
Melief
C J
CJ
D000818:Animals; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D010455:Peptides / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D010455:Peptides; D014614:Vaccines, Synthetic; D014764:Viral Proteins